On the afternoon of February 11, Shanghai’s first centralized signing of foreign investment projects in 2022 took place.

The representatives who participated in the signing included those who announced new projects, and those who expressed that they would increase the capital of the projects. They were optimistic about China and Shanghai, which resonated with the city’s “four functions” and “five-oriented economy.”

Global leaders in high-tech choose to increase their holdings in China

Carl Zeiss AG. is a leading German company in the manufacturing of optical systems, industrial measuring instruments, and medical equipment. The contents of the signing at this event are two new projects: the investment of 30 million US dollars, and the proposed establishment of Carl Zeiss Medical Technology (Shanghai) Investment Co., Ltd.

Shanghai’s first centralized signing of foreign-funded projects in 2022-SHLINGANGIC

CINIC HOLDINGS LIMITED (Hong Kong) is a holding company specializing in high-performance chemical materials. It has set up two factories in Qingpu, Shanghai and Taixing, Jiangsu. The content of the signing is a total investment of 100 million US dollars, and the company is planning to build its Asia-Pacific regional headquarters on a total of 58 acres of land in the Hangzhou Bay Development Zone of Fengxian District, Shanghai.
It is understood that once the project reaches production the annual output value is expected to exceed 1 billion yuan, and the annual tax revenue will exceed 100 million yuan.

Shanghai’s first centralized signing of foreign-funded projects in 2022-SHLINGANGIC

Actively connect with the digital transformation of Shanghai

KPMG is a global network of professional services members. In 1993, a representative office was established in Shanghai. At present, KPMG Shanghai covers a total of 6 entities with a total staff size of more than 3,000.

Shanghai Jiuweier Technology Co., Ltd. is a wholly foreign-owned enterprise established in China by Juhao Global Co., Ltd., which is listed on NASDAQ in the United States. The content of this signing is the new establishment of the company. The company’s registered capital is 58 million US dollars, and it has paid 24.839 million US dollars so far. The main business is an e-commerce company that sells health care products, cosmetics, and daily necessities.

Optimistic about the high-tech medical industry

China’s huge domestic demand market has made foreign companies pay more and more attention to its high-tech medical industry

Zai Lab (Shanghai) Co., Ltd. is a globally operating innovative biopharmaceutical company based in China dedicated to providing innovative medicines in the fields of cancer, autoimmunity, and infectious diseases to patients in China and around the world. Headquartered in Shanghai in 2014, it has 8 operation centers around the world and more than 1,900 employees. The content of this contract is set to increase the capital by 100 million US dollars, which will be mainly used for the upgrade of the R&D center.

Anuoluo Pharmaceutical (Shanghai) Co., Ltd. is also an innovative biopharmaceutical company. Shuyuan Yao, CEO of the company, participated in the signing and introduced that in 2021, the company set up a corporate headquarters in the Lingang Special Area, with a total investment of more than 250 million yuan. He said that the project is expected to be completed in mid-2022 and will become China’s leading clinical development and commercial production base for general-purpose cell therapy products. “Lingang Special Area has given us good policy support in terms of raw material and equipment import, foreign exchange and employment, and we have full confidence in the company’s prospects.”